{"nctId":"NCT02507687","briefTitle":"Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension","startDateStruct":{"date":"2015-08-27","type":"ACTUAL"},"conditions":["Glaucoma, Open-Angle","Ocular Hypertension"],"count":240,"armGroups":[{"label":"Stage 1: SLT (Primary Eye) / Bimatoprost SR 15 µg (Contralateral Eye)","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]},{"label":"Stage 1: Bimatoprost SR 15 µg (Primary Eye) / SLT (Contralateral Eye)","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]},{"label":"Stage 2: SLT (Primary Eye) / Bimatoprost SR 10 µg (Contralateral Eye)","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]},{"label":"Stage 2: Bimatoprost SR 10 µg (Primary Eye) / SLT (Contralateral Eye)","type":"EXPERIMENTAL","interventionNames":["Drug: Bimatoprost SR","Drug: Sham Bimatoprost SR","Procedure: Selective Laser Trabeculoplasty","Procedure: Sham Selective Laser Trabeculoplasty"]}],"interventions":[{"name":"Bimatoprost SR","otherNames":[]},{"name":"Sham Bimatoprost SR","otherNames":[]},{"name":"Selective Laser Trabeculoplasty","otherNames":[]},{"name":"Sham Selective Laser Trabeculoplasty","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of either open-angle glaucoma or ocular hypertension in each eye that require IOP lowering treatment.\n* In the investigator's opinion, patient's IOP is not adequately managed with topical medication for reasons other than medication efficacy (eg, due to intolerance or nonadherence).\n* In the investigator's opinion, both eyes can be treated adequately with topical prostamide, prostaglandin, or prostaglandin analog eye drops as the sole therapy if medication was taken as directed, or with SLT monotherapy.\n\nExclusion Criteria:\n\n* History of previous laser trabeculoplasty\n* History or evidence of complicated cataract surgery: eg, surgery resulting in complicated lens placement (such as anterior chamber intraocular lens implant \\[IOL\\], sulcus IOL, aphakia, etc) or intraoperative complications (such as a posterior capsular tear \\[with or without vitreous loss\\], substantial iris trauma, etc) or history of phakic IOL insertion for refractive error correction\n* Intraocular surgery (including cataract surgery) and/or any ocular laser surgery within the 6 months prior to treatment\n* Previous use of commercially available Bimatoprost SR; concurrent enrollment in another Allergan Bimatoprost SR study; or previous enrollment in which an implant was received.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Intraocular Pressure at Week 4","description":"Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. A mixed-effects model with repeated measures (MMRM) was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"0.28"},{"groupId":"OG001","value":"-6.8","spread":"0.28"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Intraocular Pressure at Week 12","description":"Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. An MMRM was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"0.30"},{"groupId":"OG001","value":"-6.9","spread":"0.30"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Intraocular Pressure at Week 24","description":"Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. An MMRM was used for the analysis. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":"0.28"},{"groupId":"OG001","value":"-6.9","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Time to Initial Use of Non-study IOP-lowering Treatment","description":"The time from the date of initial treatment to the date date of first use of non-study IOP-lowering treatment (rescue) was analyzed using the Kaplan-Meier method.\n\nIf a participant did not use any non-study IOP-lowering treatment in an eye, then the event (initial use of non-study IOP-lowering treatment) time was censored at the study exit date or the last visit date if the study exit date was not available.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"276","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"732","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Eyes Achieving ≥ 20% Reduction in IOP From Baseline Regardless of Cycle","description":"Intraocular pressure was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer.\n\nFor by-cycle analyses, cycle number refers to the administration cycle for bimatoprost SR, or sham bimatoprost SR administration in SLT-treated eyes. For SLT-treated eyes cycle number does not refer to SLT administrations, because SLT was only performed once (Day 1). The Day/Week number refers to the number of days/weeks after bimatoprost SR/sham bimatoprost SR administration.\n\nIOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null},{"groupId":"OG001","value":"86.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"75.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.1","spread":null},{"groupId":"OG001","value":"71.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":null},{"groupId":"OG001","value":"67.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.5","spread":null},{"groupId":"OG001","value":"62.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":null},{"groupId":"OG001","value":"55.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.1","spread":null},{"groupId":"OG001","value":"62.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.5","spread":null},{"groupId":"OG001","value":"57.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"70.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.4","spread":null},{"groupId":"OG001","value":"66.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"65.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.0","spread":null},{"groupId":"OG001","value":"61.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":null},{"groupId":"OG001","value":"70.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"60.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.5","spread":null},{"groupId":"OG001","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"69.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in IOP at Weeks 8, 15, and 20","description":"IOP was measured at 8 am (Hour 0) at each visit in each eye using the Goldmann applanation tonometer. A negative change from Baseline indicates a decrease (improvement) in intraocular pressure. IOP measurements obtained after initiation of non-study IOP-lowering treatment in an eye were excluded from the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.1","spread":"3.00"},{"groupId":"OG001","value":"25.2","spread":"2.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"3.52"},{"groupId":"OG001","value":"-6.8","spread":"3.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.0","spread":"3.58"},{"groupId":"OG001","value":"-6.0","spread":"4.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9","spread":"3.44"},{"groupId":"OG001","value":"-6.4","spread":"3.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":56},"commonTop":["CONJUNCTIVAL HYPERAEMIA","INTRAOCULAR PRESSURE INCREASED","DRY EYE","PUNCTATE KERATITIS","VISUAL FIELD DEFECT"]}}}